Diphtheria: all 267 studies
Page 1 of 3. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)RecruitingNCT07894055Phase 2
- A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine AdsorbedRecruitingNCT07891104Phase 1/2
- Study of BK1803 in Healthy InfantsNot yet recruitingNCT07793513Phase 3
- A Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined VaccineNot yet recruitingNCT07744347
- Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response in Thai Infants up to 15-18 Months OldNot yet recruitingNCT07621341Phase 4
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)Not yet recruitingNCT07492303Phase 1
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) VaccineNot yet recruitingNCT07418372Phase 1/2
- Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined VaccineRecruitingNCT07203755Phase 1
- Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical TrialRecruitingNCT07112144Phase 3
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in PregnancyRecruitingNCT07097012Phase 4
- A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy AdultsRecruitingNCT06997627Phase 1/2
- Enhancing Maternal Vaccine Knowledge and Uptake: The InTroDuce-Programme TrialRecruitingNCT06815250Not applicable
- Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgeNot yet recruitingNCT06618196Phase 2
- Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old InfantsRecruitingNCT06605755Not applicable
- Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined VaccineRecruitingNCT06184542Phase 1
- Assessing Interventions to Increase Tdap Acceptance for Non-birthing Partners in PregnancyRecruitingNCT06135636Phase 4
- A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy AdultsNot yet recruitingNCT05952596Phase 1
- PFAS Exposure and Immune Response to Vaccination in AdultsCompletedNCT06588530Phase 4Results posted
- Safety and Immunogenicity Study of Tdap Vaccinations for Plasma DonorsCompletedNCT05662852Phase 2Results posted
- A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and ToddlersCompletedNCT04535037Phase 4Results posted
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedNCT04398706Phase 2Results posted
- A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARSCompletedNCT04071158Phase 2Results posted
- Confirmatory Study of BK1310 in Healthy InfantsCompletedNCT03891758Phase 3Results posted
- Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their InfantsCompletedNCT03589768Phase 2Results posted
- Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian SubjectsCompletedNCT03311659Phase 3Results posted
- Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy InfantsCompletedNCT02907216Phase 4Results posted
- A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in RussiaCompletedNCT02858440Phase 3Results posted
- Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02853929Phase 4Results posted
- A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.CompletedNCT02757950Results posted
- Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy SubjectsCompletedNCT02587520Phase 1/2Results posted
- Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02422264Phase 4Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant WomenCompletedNCT02377349Phase 4Results posted
- Study of BK1301 (DTaP Vaccine) as a Booster in AdolescentsCompletedNCT02118961Phase 3Results posted
- Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy InfantsCompletedNCT02096263Phase 3Results posted
- Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years OldCompletedNCT02089347Phase 3Results posted
- Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese ChildrenCompletedNCT01988857Phase 3Results posted
- Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at BirthCompletedNCT01948193Phase 3Results posted
- Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in ChinaCompletedNCT01933776Phase 1Results posted
- Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in KoreaCompletedNCT01929291Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of AgeCompletedNCT01767376Phase 3Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsCompletedNCT01755689Phase 3Results posted
- Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young AdultsCompletedNCT01738477Phase 3Results posted
- Tdap Vaccine in Post-Partum WomenCompletedNCT01711645Phase 4Results posted
- Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in AdolescentsCompletedNCT01689324Phase 1/2Results posted
- Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of AgeCompletedNCT01659996Phase 4Results posted
- Immunogenicity of Adacel® and BOOSTRIX® Vaccines in AdolescentsCompletedNCT01629589Phase 4Results posted
- Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese ToddlersCompletedNCT01577732Phase 3Results posted
- Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 YearsCompletedNCT01529645Phase 1Results posted
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)CompletedNCT01480258Phase 3Results posted
- Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedNCT01453998Phase 2Results posted
- Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) VaccineCompletedNCT01449812Phase 3Results posted
- Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy InfantsCompletedNCT01444781Phase 3Results posted
- Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous DoseCompletedNCT01439165Phase 4Results posted
- Regulatory Post-Marketing Surveillance Study for TETRAXIM™CompletedNCT01437423Phase 4Results posted
- Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type BCompletedNCT01362517Phase 3Results posted
- Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old AdolescentsCompletedNCT01362322Phase 4Results posted
- Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™CompletedNCT01358825Phase 4Results posted
- Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood VaccinationCompletedNCT01357720Phase 4Results posted
- Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) VaccineCompletedNCT01353703Phase 3Results posted
- Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of AgeCompletedNCT01346293Phase 3Results posted
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)CompletedNCT01341639Phase 3Results posted
- A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)CompletedNCT01340937Phase 3Results posted
- Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)CompletedNCT01337167Phase 3Results posted
- Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted AdultsCompletedNCT01323959Phase 4Results posted
- Study of Adacel® Vaccine Administered to Persons 10 Years of AgeCompletedNCT01311557Phase 4Results posted
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib VaccineCompletedNCT01309646Phase 3Results posted
- Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedNCT01248884Phase 2Results posted
- Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old ChildrenCompletedNCT01245049Phase 3Results posted
- A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American InfantsCompletedNCT01177722Phase 3Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseCompletedNCT01171989Phase 2Results posted
- Evaluation of Boostrix™10 Years After Previous Booster VaccinationCompletedNCT01147900Phase 4Results posted
- Post Marketing Surveillance for ADACEL™ in South KoreaCompletedNCT01137435Phase 4Results posted
- Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy ToddlersCompletedNCT01106092Phase 2Results posted
- Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in RussiaCompletedNCT01094171Phase 4Results posted
- Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy InfantsCompletedNCT01090453Phase 2Results posted
- Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ VaccineCompletedNCT01086423Phase 3Results posted
- A Study to Assess the Safety of Adacel® VaccineCompletedNCT01040052Phase 3Results posted
- Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeCompletedNCT00970307Phase 2Results posted
- Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)CompletedNCT00964028Phase 3Results posted
- Post Market Surveillance for Infanrix™CompletedNCT00908115Results posted
- Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.TerminatedNCT00871741Phase 2Results posted
- Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 YearsCompletedNCT00871117Phase 3Results posted
- Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.CompletedNCT00871000Phase 3Results posted
- Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.CompletedNCT00835237Phase 3Results posted
- Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian InfantsCompletedNCT00831753Phase 3Results posted
- Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean InfantsCompletedNCT00831311Phase 2Results posted
- Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™CompletedNCT00802867Phase 4Results posted
- Immunogenicity and Safety of Adacel Polio VaccineCompletedNCT00797511Phase 3Results posted
- Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap VaccineCompletedNCT00777257Phase 4Results posted
- Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™CompletedNCT00772928Phase 3Results posted
- Retrospective Survey of Safety of Fourth Dose Pentacel® in ChildrenCompletedNCT00772369Results posted
- Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in InfantsCompletedNCT00753649Phase 4Results posted
- Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous DoseCompletedNCT00712959Phase 4Results posted
- Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in ChildrenCompletedNCT00696423Phase 3Results posted
- Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™CompletedNCT00654901Phase 3Results posted
- Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio VaccineCompletedNCT00635128Phase 4Results posted
- Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib VaccineCompletedNCT00627458Phase 2Results posted
- Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish InfantsCompletedNCT00619502Phase 3Results posted
- Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old ChildrenCompletedNCT00611559Phase 4Results posted
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.CompletedNCT00610168Phase 4Results posted